

22 April 2016

Omniblend Innovation Transaction Completed

Highlights

- Successful completion of Tranche 1 investment in Omniblend Innovation
- EVE now holds a ~25% interest in Omniblend Innovation, which is set to increase to ~40% by September 2016 following the completion of Tranche 2
- EVE intends to work closely with Omniblend Innovation's management team toward an IPO of the Company, within the next 2 years with EVE shareholders to receive a preferential entitlement

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to announce that settlement of Tranche 1 of the Omniblend Innovation investment has been completed. This Tranche 1 investment gives EVE approximately a 25% stake in Omniblend Innovation.

EVE will increase its interest in Omniblend Innovation to ~40% by 30 September 2016, under the revised payment terms for the Tranche 2 investment (see ASX announcement on 1 April 2016). Additionally, EVE has secured the right to publicly list Omniblend Innovation within two years, providing EVE shareholders with preferential entitlement to participate in the listing.

Omniblend Innovation overview

Omniblend Innovation is a Melbourne based private medical food technology company focused on the creation of products, tools and technologies for foods for special medical purposes (FSANZ 2.9.5). The Omniblend Innovation technology was partially funded from a substantial Commercialisation Australia grant from 2012 to 2015 to develop a pre-meal drink for the dietary management of type 2 diabetes.

Its lead product, GlucoControl™ is a patented food-grade pre-meal drink clinically shown to help manage T2D by reducing blood glucose spikes after meals by between 33-38 per cent. The key patented discovery behind GlucoControl™ is a method for reducing necessary ingredients in an effective pre-meal drink for people with type 2 diabetes. For the first time an effective pre-meal drink technology has become commercially viable and acceptable to consumers.

Clear and focused growth plans

The funds from the EVE investment will be used to support the roll-out of GlucoControl™ in Australia and New Zealand, as well as expedite expansion into high value overseas markets including China and the USA. For these larger export markets, Omniblend Innovation will pursue royalty-based marketing and distribution partnerships. Additionally, Omniblend Innovation will continue to develop its pipeline of next generation and complementary products.

-ENDS-

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au

Justin Kelly
Media & Capital Partners
0408 215 858
justin.kelly@mcpartners.com.au

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au

For personal use only